Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Reactive Antibodies: December 2019-January 2020

被引：63

作者：

Basavaraju, Sridhar, V ^{[1
]}

Patton, Monica E. ^{[1
]}

Grimm, Kacie ^{[2
]}

Rasheed, Mohammed Ata Ur ^{[2
]}

Lester, Sandra ^{[2
]}

Mills, Lisa ^{[3
]}

Stumpf, Megan ^{[3
]}

Freeman, Brandi ^{[1
]}

Tamin, Azaibi ^{[1
]}

Harcourt, Jennifer ^{[1
]}

Schiffer, Jarad ^{[1
]}

Semenova, Vera ^{[1
]}

Li, Han ^{[1
]}

Alston, Bailey ^{[4
]}

Ategbole, Muyiwa ^{[5
]}

Bolcen, Shanna ^{[1
]}

Boulay, Darbi ^{[1
]}

Browning, Peter ^{[1
]}

Cronin, Li ^{[1
]}

David, Ebenezer ^{[6
]}

Desai, Rita ^{[1
]}

Epperson, Monica ^{[1
]}

Gorantla, Yamini ^{[5
]}

Jia, Tao ^{[1
]}

Maniatis, Panagiotis ^{[1
]}

Moss, Kimberly ^{[4
]}

Ortiz, Kristina ^{[4
]}

Park, So Hee ^{[4
]}

Patel, Palak ^{[6
]}

Qin, Yunlong ^{[4
]}

Steward-Clark, Evelene ^{[1
]}

Tatum, Heather ^{[5
]}

Vogan, Andrew ^{[4
]}

Zellner, Briana ^{[7
]}

Drobeniuc, Jan ^{[1
]}

Sapiano, Matthew R. P. ^{[1
]}

Havers, Fiona ^{[1
]}

Reed, Carrie ^{[1
]}

Gerber, Susan ^{[1
]}

Thornburg, Natalie J. ^{[1
]}

Stramer, Susan L. ^{[2
]}

机构：

[1] CDCP, Atlanta, GA 30333 USA

[2] Amer Red Cross, Sci Affairs, Gaithersburg, MD USA

[3] Synergy Amer Inc, Atlanta, GA USA

[4] Eagle Global Sci, Atlanta, GA USA

[5] IHRC, Atlanta, GA USA

[6] CFD Res Corp, Huntsville, AL USA

[7] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA

来源：

CLINICAL INFECTIOUS DISEASES | 2021年 / 72卷 / 12期

关键词：

SARS-CoV-2; blood donors; antibody;

D O I：

10.1093/cid/ciaa1785

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was first identified in Wuhan, China, in December 2019, with subsequent worldwide spread. The first US cases were identified in January 2020. Methods. To determine if SARS-CoV-2-reactive antibodies were present in sera prior to the first identified case in the United States on 19 January 2020, residual archived samples from 7389 routine blood donations collected by the American Red Cross from 13 December 2019 to 17 January 2020 from donors resident in 9 states (California, Connecticut, Iowa, Massachusetts, Michigan, Oregon, Rhode Island, Washington, and Wisconsin) were tested at the Centers for Disease Control and Prevention for anti-SARS-CoV-2 antibodies. Specimens reactive by pan-immunoglobulin (pan-Ig) enzyme-linked immunosorbent assay (ELISA) against the full spike protein were tested by IgG and IgM ELISAs, microneutralization test, Ortho total Ig S1 ELISA, and receptor-binding domain/ACE2 blocking activity assay. Results. Of the 7389 samples, 106 were reactive by pan-Ig. Of these 106 specimens, 90 were available for further testing. Eighty-four of 90 had neutralizing activity, 1 had S1 binding activity, and 1 had receptor-binding domain/ACE2 blocking activity >50%, suggesting the presence of anti-SARS-CoV-2-reactive antibodies. Donations with reactivity occurred in all 9 states. Conclusions. These findings suggest that SARS-CoV-2 may have been introduced into the United States prior to 19 January 2020.

引用

页码：E1004 / E1009

页数：6

共 29 条

[1]

AABB, 2016, FULL LENGTH BLOOD DO

[2] MODELLING THE PANDEMIC The simulations driving the world's response to COVID-19 [J].

Adam, David .

NATURE, 2020, 580 (7803) :316-318

[3] Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate [J].

Addetia, Amin ;

Crawford, Katharine H. D. ;

Dingens, Adam ;

Zhu, Haiying ;

Roychoudhury, Pavitra ;

Huang, Meei-Li ;

Jerome, Keith R. ;

Bloom, Jesse D. ;

Greninger, Alexander L. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2020, 58 (11)

[4] The proximal origin of SARS-CoV-2 [J].

Andersen, Kristian G. ;

Rambaut, Andrew ;

Lipkin, W. Ian ;

Holmes, Edward C. ;

Garry, Robert F. .

NATURE MEDICINE, 2020, 26 (04) :450-452

[5]

Bedford T, CRYPTIC TRANSMISSION

[6] Implications of the impact of prevalence on test thresholds and outcomes: Lessons from tuberculosis [J].

Tanya GK Bentley ;

Antonino Catanzaro ;

Theodore G Ganiats .

BMC Research Notes, 5 (1)

[7]

California Department of Public Health, 2020, CDC CONF 1 POSS INST

[8] Use of Blood Donor Screening Data to Estimate Zika Virus Incidence, Puerto Rico, April-August 2016 [J].

Chevalier, Michelle S. ;

Biggerstaff, Brad J. ;

Basavaraju, Sridhar V. ;

Ocfemia, M. Cheryl Banez ;

Alsina, Jose O. ;

Climent-Peris, Consuelo ;

Moseley, Robin R. ;

Chung, Koo-Whang ;

Rivera-Garcia, Brenda ;

Bello-Pagan, Melissa ;

Pate, Lisa L. ;

Galel, Susan A. ;

Williamson, Phillip ;

Kuehnert, Matthew J. .

EMERGING INFECTIOUS DISEASES, 2017, 23 (05) :790-795

[9] Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States [J].

Kujawski S.A. ;

Wong K.K. ;

Collins J.P. ;

Epstein L. ;

Killerby M.E. ;

Midgley C.M. ;

Abedi G.R. ;

Ahmed N.S. ;

Almendares O. ;

Alvarez F.N. ;

Anderson K.N. ;

Balter S. ;

Barry V. ;

Bartlett K. ;

Beer K. ;

Ben-Aderet M.A. ;

Benowitz I. ;

Biggs H.M. ;

Binder A.M. ;

Black S.R. ;

Bonin B. ;

Bozio C.H. ;

Brown C.M. ;

Bruce H. ;

Bryant-Genevier J. ;

Budd A. ;

Buell D. ;

Bystritsky R. ;

Cates J. ;

Charles E.M. ;

Chatham-Stephens K. ;

Chea N. ;

Chiou H. ;

Christiansen D. ;

Chu V. ;

Cody S. ;

Cohen M. ;

Conners E.E. ;

Curns A.T. ;

Dasari V. ;

Dawson P. ;

DeSalvo T. ;

Diaz G. ;

Donahue M. ;

Donovan S. ;

Duca L.M. ;

Erickson K. ;

Esona M.D. ;

Evans S. ;

Falk J. .

NATURE MEDICINE, 2020, 26 (06) :861-+

[10] SARS-CoV-2 was already spreading in France in late December 2019 [J].

Deslandes, A. ;

Berti, V ;

Tandjaoui-Lambotte, Y. ;

Alloui, Chakib ;

Carbonnelle, E. ;

Zahar, J. R. ;

Brichler, S. ;

Cohen, Yves .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (06)

← 1 2 3 →